For instance, avelumab (MSB0010718C) is a monoclonal antibody that targets PD-L1 and exhibits antibody-dependent cell-mediated cytotoxicity (ADCC), thereby significantly enhancing the killing effects of high-affinity natural killer cells in head and neck squamous cell carcinoma (HNSCC) [17, 18]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.